Global N-Formyl Peptide Receptor 2 Market Size By Type (TR-8, NCP-70X), By Application (Inflammation, Type 2 Diabetes), By Region, And Segment Forecasts, 2023 to 2032

The Global N-Formyl Peptide Receptor 2 (FPR2) Market was valued at USD 612 million in 2023 and is projected to reach USD 1.38 billion by 2031, growing at a CAGR of 10.5% during the forecast period from 2023 to 2031. FPR2, a G-protein coupled receptor, is gaining significant traction in pharmaceutical research for its role in mediating immune responses and inflammation regulation. Increased research into inflammation-driven diseases, along with the receptor's therapeutic potential in oncology, neurodegenerative disorders, and autoimmune diseases, is propelling market growth.

Drivers

1. Increasing Prevalence of Inflammatory and Autoimmune Diseases

The rising incidence of chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis is fueling demand for therapies targeting FPR2.

2. Advancements in Drug Discovery Technologies

Innovative drug development platforms and high-throughput screening techniques have enhanced the identification of FPR2 modulators, accelerating preclinical and clinical research.

3. Growing Interest in Immunomodulatory Therapies

Pharmaceutical companies are increasingly exploring immunomodulatory therapies as a safer, more targeted approach to managing chronic diseases, with FPR2 being a key therapeutic target.

Restraints

1. Limited Clinical Validation

Despite strong preclinical data, limited clinical trials and a lack of approved therapies specifically targeting FPR2 restrict commercial scalability.

2. High R&D Costs and Regulatory Hurdles

Bringing new FPR2-targeting drugs to market requires significant investment in research, development, and compliance with complex regulatory frameworks, posing a barrier for smaller firms.

Opportunity

1. Expanding Oncology and CNS Therapeutic Pipeline

FPR2's emerging role in modulating tumor microenvironments and neuroinflammation presents lucrative opportunities for oncology and CNS drug developers.

2. Strategic Collaborations and Licensing Deals

Major biopharma companies are increasingly forming strategic alliances with biotech firms to accelerate FPR2-targeting drug development through shared resources and expertise.

Market by System Type Insights

By receptor targeting mechanism, the Agonist-based Therapeutics segment led the market in 2023, driven by their role in resolving inflammation and restoring immune balance. The Antagonist-based Therapeutics segment is anticipated to gain momentum over the forecast period, especially in oncology and autoimmune indications.

Market by End-Use Insights

In terms of end-use, Pharmaceutical & Biotechnology Companies held the largest share in 2023 due to robust R&D pipelines and early-phase trials. Academic Research Institutes are also key contributors, driven by ongoing basic science research and government-funded grants.

Market by Regional Insights

North America dominated the global N-Formyl Peptide Receptor 2 market in 2023, supported by a strong biopharmaceutical sector, advanced healthcare infrastructure, and high R&D investment. Europe followed closely, benefiting from collaborative research efforts and a growing number of clinical trials. Meanwhile, Asia-Pacific is expected to witness the fastest growth through 2031, propelled by emerging biotech hubs and rising healthcare expenditure in China and India.

Competitive Scenario

Key players in the Global N-Formyl Peptide Receptor 2 Market include:

Domain Therapeutics

Aeterna Zentaris

AbbVie Inc.

Johnson & Johnson

Novartis AG

Sanofi

Bristol-Myers Squibb

Aurigene Discovery

Biovian Oy

These companies are engaged in FPR2-focused research, partnerships, licensing deals, and expanding their clinical pipelines to establish leadership in this niche but promising market.

Scope of Work – Global N-Formyl Peptide Receptor 2 Market

Key Market Developments

2023: Domain Therapeutics advanced its FPR2 agonist program into IND-enabling studies for chronic inflammatory conditions.

2024: AbbVie and a biotech partner announced a co-development deal focused on FPR2-targeted therapeutics for autoimmune diseases.

2025: Novartis initiated Phase I trials on an FPR2 antagonist aimed at solid tumors, marking its entry into inflammation-modulated oncology.

FAQs

1) What is the current market size of the Global N-Formyl Peptide Receptor 2 Market?

The market was valued at USD 612 million in 2023.

2) What is the major growth driver of the Global N-Formyl Peptide Receptor 2 Market?

The major growth driver is the increasing prevalence of inflammatory and autoimmune diseases and the receptor’s potential as a therapeutic target.

3) Which is the largest region during the forecast period in the Global N-Formyl Peptide Receptor 2 Market?

North America is expected to remain the largest region through 2031.

4) Which segment accounted for the largest market share in the Global N-Formyl Peptide Receptor 2 Market?

The Agonist-based Therapeutics segment accounted for the largest share in 2023.

5) Who are the key market players in the Global N-Formyl Peptide Receptor 2 Market?

Key players include Domain Therapeutics, AbbVie, Novartis, Johnson & Johnson, and Sanofi.